This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Boehringer Ingelheim Pharmaceuticals, Inc.
Reference
Zhou Z, et al. Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis. Advances in Therapy : 30 Mar 2019. Available from: URL: http://doi.org/10.1007/s12325-019-00929-2
Rights and permissions
About this article
Cite this article
Systemic sclerosis with interstitial lung disease: substantial burden. PharmacoEcon Outcomes News 826, 30 (2019). https://doi.org/10.1007/s40274-019-5832-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5832-7